What's Going On With BioVie Stock on Tuesday?
BioVie reported Phase 2 ADDRESS-LC trial results evaluating bezisterim for Long COVID, showing significant subgroup improvements.
Stocks · News reference
Nasdaq Down 50 Points; US Foods Posts Upbeat Earnings
US stocks trade mixed, Nasdaq falls 50 points. Energy shares up 1.3%, tech stocks down 0.5%. US Foods beats earnings, Clearone Inc surges 203%.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BioVie shares are trading lower. The company announced topline results from Phase 2 ADDRESS‑LC trial evaluating Bezisterim for the treatment of neurological symptoms associated with long COVID.
Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times
BioVie Announces Phase 2 ADDRESS-LC Trial Results Of Bezisterim In Long COVID
Statistically significant benefits observed in bezisterim-treated Long COVID patients in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post‑exertional malaiseBezisterim showed a
8-K filing — CLEARONE INC (CLRO)
Filed: 2026-08-11 AccNo: 0001753926-26-001428 Size: 909 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
12 Information Technology Stocks Moving In Tuesday's Intraday Session
Gainers Quantum (NASDAQ:QMCO) stock rose 56.7% to $18.45 during Tuesday's regular session. The market value of their outstanding shares is at $463.8 million. As per the news, the Q1 earnings report came out